FLT3 inhibitors in acute myeloid leukemia

Table 5 Clinical trials of quizartinib for AML therapy

Study agents	Other agents	Disease	Dose	No Pts	Clinical trials	Response	Reference
Quizartinib	Chemotherapy	Untreated	40–60 mg/day	19	Phase I	OR 84%	[53]
Quizartinib		Relapsed Refractory	12–450 mg/day	76	Phase I	OR 30%	[55]
Quizartinib		Relapsed Refractory	30 mg/day 60 mg/day	76	Phase 2b	CRc 47%	[58]
Quizartinib	Cytarabine Etoposide	Relapsed	40 mg/day 60 mg/day	22	Phase I	2 CR, 1 CRp, 1 CRi, 10 SD, 3 PD	[59]

OR overall response, CR complete remission, CRp complete remission with incomplete platelet recovery, CRi complete response with incomplete neutrophil and platelet recovery, CRc composite complete remission, SD stable disease, PD progress disease

ISSN: 1756-8722